Press Releases
June 10, 2020
Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders
Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders